The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model

Pharmacology, Toxicology and Pharmaceutical Science

• Mouse Model 100%
• Dipeptidyl Peptidase IV Inhibitor 100%
• Thrombosis 100%
• Inflammation 100%
• Sepsis 100%
• Linagliptin 100%
• Lipopolysaccharide 42%
• Anticoagulant Agent 42%
• Tumor Necrosis Factor 28%
• Mouse 28%
• Anti-Inflammatory Drug 28%
• Endothelial Nitric Oxide Synthase 14%
• Alternative Complement Pathway C3 C5 Convertase 14%
• Nuclear Factor 14%
• Interleukin 1 14%
• Antiinflammatory Activity 14%
• Intercellular Adhesion Molecule 1 14%
• Antidiabetic Agent 14%
• Systemic Inflammatory Response Syndrome 14%
• Ethinylestradiol Plus Norethisterone Acetate 14%
• Hypercoagulability 14%
• Pathophysiology 14%
• Thromboplastin 14%

Medicine and Dentistry

• Sepsis 100%
• Thrombosis 100%
• Dipeptidyl Peptidase-4 Inhibitor 100%
• Linagliptin 100%
• Antithrombotic 42%
• Lipopolysaccharide 42%
• Tumor Necrosis Factor 28%
• Anti-Inflammatory Drug 28%
• Human Umbilical Vein Endothelial Cell 28%
• In Vitro 14%
• Endothelial Nitric Oxide Synthase 14%
• Pathophysiology 14%
• Interleukin 1 14%
• Nuclear Factor 14%
• Antiinflammatory Activity 14%
• Intercellular Adhesion Molecule 1 14%
• Antidiabetic Agent 14%
• Alternative Complement Pathway C3 C5 Convertase 14%
• Blood Glucose 14%
• Thromboplastin 14%
• Hypercoagulability 14%
• Microcirculation 14%
• Ethinylestradiol Plus Norethisterone Acetate 14%
• Systemic Inflammatory Response Syndrome 14%